Jordi Jornet-Plaza
@jordijornet.bsky.social
📤 35
📥 26
📝 0
PhD student in Neuropharmacology Research Group🧠 at
@uib.cat
reposted by
Jordi Jornet-Plaza
Infosalut
9 months ago
#PublicaSalutIB 🐀💊
@jordijornet.bsky.social
,
@sandracorvi.bsky.social
i
@garciafusterlab.bsky.social
de
@idisba.bsky.social
han publicat la caracterització de l'ús terapèutic de la ketamina en rates adolescents
https://www.infosalut.com/17236
https://doi.org/10.1016/j.biopha.2024.117781
0
2
4
reposted by
Jordi Jornet-Plaza
Julia Garcia-Fuster
about 1 year ago
Here is the link to "Characterizing the therapeutical use of ketamine for adolescent rats of both sexes: Antidepressant-like efficacy and safety profile": our latest publication with
@jordijornet.bsky.social
as first author:
www.sciencedirect.com/science/arti...
loading . . .
Characterizing the therapeutical use of ketamine for adolescent rats of both sexes: Antidepressant-like efficacy and safety profile
While ketamine was approved for treatment-resistant depression in adult patients, its efficacy and safety profile for adolescence still requires furth…
https://www.sciencedirect.com/science/article/pii/S0753332224016688
0
4
2
reposted by
Jordi Jornet-Plaza
Julia Garcia-Fuster
about 1 year ago
Celebrating a year full of accomplishments with these great bunch of people. Happy holidays 🙂
0
5
2
reposted by
Jordi Jornet-Plaza
bioRxiv Pharmacology and Toxicology
about 1 year ago
Safety concerns following the use of ketamine as a potential antidepressant for adolescent rats of both sexes https://www.biorxiv.org/content/10.1101/2024.11.08.622617v1
loading . . .
Safety concerns following the use of ketamine as a potential antidepressant for adolescent rats of both sexes https://www.biorxiv.org/content/10.1101/2024.11.08.622617v1
While ketamine is already approved for treatment resistant depression in adult patients, its efficac
https://www.biorxiv.org/content/10.1101/2024.11.08.622617v1
0
2
2
you reached the end!!
feeds!
log in